NASDAQ:COGT 10 November 2025

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences shares climbed about 8% Wednesday after the company set a 2026 timetable for U.S. filings of its lead drug, bezuclastinib. Cogent expects FDA acceptance of its first application by the end of February and aims for a possible commercial launch in the second half of 2026. The stock traded at $38.17 midday. The company began the year with about $900 million in cash.

14 January 2026

NASDAQ:COGT·Stock Market

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

Cogent Biosciences shares fell 2.5% to $36.19 Wednesday after the company filed its first U.S. new drug application for bezuclastinib in non-advanced systemic mastocytosis. SEC filings showed four senior executives sold shares late last week, including CFO John L. Green and Chief Medical Officer Jessica Sachs.

31 December 2025

Biotechnology·NASDAQ:COGT·Stock Market

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Cogent Biosciences shares fell 2.7% to $36.88 Tuesday after the company submitted a New Drug Application to the FDA for bezuclastinib in nonadvanced systemic mastocytosis. The filing follows positive trial data and an FDA Breakthrough Therapy Designation. The broader biotech sector also declined, with major ETFs down more than 1%.

30 December 2025

NASDAQ:COGT·Pharmaceuticals·Stock Market

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences reported its Phase 3 PEAK trial showed bezuclastinib plus sunitinib extended median progression-free survival to 16.5 months versus 9.2 months for sunitinib alone in second-line GIST (HR=0.50; p

10 November 2025

Biotechnology·NASDAQ:COGT·Pharmaceutical News·Stock Market

Kennametal (KMT) Valuation Examined After Recent Share Price Decline
March 20, 2026, 3:19 AM EDT. Kennametal (KMT) shares fell about 9% last week and 10% over the month following a strong 22% gain in three months. Despite a 67.9% total shareholder return over one year, recent pullbacks raise questions on future growth prospects. The stock trades slightly below analyst targets but well below some intrinsic value estimates, with a fair value around $37.13 versus a $35.18 close. Cost-cutting efforts, including $125 million in expected savings by fiscal 2028, aim to improve margins. However, risks include persistent weak demand and potential delay in realizing efficiencies. Investors should weigh these factors carefully amid mixed market signals and consider alternative industrial exposure opportunities.